Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 20/20 | 0.91 |
| ▸ | NOS3 | P29474 | 17/20 | 0.91 |
| ▸ | NOS2 | P35228 | 14/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838088 | 0.95 | NOS1 (1.00) | NOS1NOS3NOS2 | |
| SCHEMBL251335 | 0.85 | NOS1 (0.67) | NOS1NOS3NOS2 | |
| SCHEMBL7868256 | 0.82 | NOS3 (0.64) | NOS1NOS3NOS2 | |
| SCHEMBL6152196 | 0.81 | NOS3 (0.69) | NOS1NOS3NOS2 | |
| SCHEMBL5833967 | 0.81 | NOS1 (1.00) | NOS1NOS3NOS2 | |
| SCHEMBL252053 | 0.81 | NOS1 (0.73) | NOS1NOS3NOS2 | |
| SCHEMBL6152955 | 0.80 | NOS3 (0.72) | NOS1NOS3NOS2 | |
| SCHEMBL5833039 | 0.80 | NOS1 (1.00) | NOS1NOS3NOS2 | |
| SCHEMBL5833428 | 0.80 | NOS1 (1.00) | NOS1NOS3NOS2 | |
| SCHEMBL6584706 | 0.80 | NOS1 (0.64) | NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1084109-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PROD INC (US) | 2005-01-26 | — | — | EP | claimed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | claimed |
| JP-2003523941-A | — | — | 2003-08-12 | — | — | JP | claimed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | claimed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | claimed |
| EP-1084109-B1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PROD INC (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | PFIZER INC | 2004-11-18 | — | — | US | disclosed |
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | LOWE JOHN A (US) | 2002-10-17 | — | — | US | disclosed |
| EP-1178784-A1 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | Pfizer Products Inc. (US) | 2002-02-13 | — | — | EP | disclosed |
| EP-1084109-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NITRIC OXIDE SYNTHASE INHIBITORS | Pfizer Products Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| WO-2000071107-A2 | NEW PHARMACEUTICAL COMBINATIONS FOR NOS INHIBITORS | PFIZER PRODUCTS INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| WO-1999062883-A1 | 2-AMINOPYRIDINES CONTAINING FUSED RING SUBSTITUENTS AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151572-A1 | PHARMACEUTICAL USES FOR NOS INHIBITORS | NOS1, NOS3, NOS2 | NOS1 1/4885NOS3 2/4885NOS2 3/4885 |
| US-20040229911-A1 | New pharmaceutical combinations for NOS inhibitors | NOS1, NOS3, NPBWR1 | NOS1 1/4885NOS3 2/4885NOS2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.